No matches

Educational Resources

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

Pulmonology

4 min

videoanimation

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

On the Surface: Restoring the Skin Barrier in Patients with AD

Dermatology

2 min

expert video

On the Surface: Restoring the Skin Barrier in Patients with AD

Type 2 Inflammation

4 min

expert video

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Dermatology

4 min

expert video

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Dermatology

3 min

expert video

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Dermatology

5 min

expert video

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Dermatology

4 min

expert video

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

Dermatology

2 min

expert video

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region

Educational Resources

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

Exploring the Mechanisms of FeNO Production in the Lungs

How Type 2 Inflammation Drives Eosinophils in Asthma

CLCI in Atopic Dermatitis Infographic

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

On the Surface: Restoring the Skin Barrier in Patients with AD

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases

Educational Resources

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

Exploring the Mechanisms of FeNO Production in the Lungs

How Type 2 Inflammation Drives Eosinophils in Asthma

CLCI in Atopic Dermatitis Infographic

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

On the Surface: Restoring the Skin Barrier in Patients with AD

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

Type 2 Cytokines Have Multiple Critical Roles in BP That Contribute to Inflammation and Itch

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD

Which Biomarkers of AD Might Be Robust Enough to Be Evaluated as a Measure of Disease Modification?

Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases